FibroScan® by echosens
gold standard solution for comprehensive management of liver health
Cirrhosis is a leading cause of mortality worldwide.
Identifying cirrhosis early in patients helps to proactively manage the disease through screenings for liver-related complications such as hepatocellular carcinoma and esophageal varices.
Agile 4 combines LSM by VCTE™ with easily accessible blood biomarkers (AST, ALT, Platelets) to help in the identification of cirrhosis in NAFLD patients to properly identify patients to start HCC and portal hypertension screening.
High clinical performances demonstrated in large external validation cohorts from different geographical origins.
Peer reviewed paper under submission
Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in non-alcoholic fatty liver disease patients with FibroScan®-based Agile scores.
A novel noninvasive score including LSM by VCTE™ and routine clinical parameters improves the identification of cirrhosis among patients with NAFLD and may reduce the necessity of liver biopsy in this patient population.
Agile 4 and Agile 3+ well predict the occurrence of liverrelated events in patients with NAFLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.
Agile 4 calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 4 is presented as an educational service intended for licensed healthcare professionals.
While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.
According to the Federal Food, Drug, and Cosmetic Act (21 CFR 880.6310) the Product is a non-device CDS.